Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01931709 · ClinicalTrials.gov registry record · NA
FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer
A NA study, sponsored by University of Washington.
- Terminated
- Registry status
- NA
- Development phase
- 35
- Enrollment target
NCT01931709: Clinical Trial NA study, sponsored by University of Washington.
NCT01931709 is a NA study that was terminated before completion, run by University of Washington. The registered enrollment target is 35 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01931709, a NA study, was terminated before completion, sponsored by University of Washington.
- TERMINATED
- Registry status
- NA
- Development phase
- 35 participants
- Enrollment target
Study Summary
This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response to treatment in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after chemotherapy may help doctors predict a patient's response to treatment and help plan the best treatment.
Primary Outcome
The primary clinical endpoint is dichotomous (yes/no) - Has patient achieved favorable microscopic pathologic response at surgery? This favorable pathologic response is defined as: 1. No evidence of microscopic invasive tumor at the primary tumor site and in regional axillary lymph nodes = Residual Cancer Burden class 0 (RCB 0) 2. Minimal invasive residual disease at primary tumor site and/or in regional axillary lymph nodes = Residual Cancer Burden class I (RCB I)
Interventions
- OTHER laboratory biomarker analysis
- RADIATION fludeoxyglucose F 18
- DEVICE positron emission tomography
- DEVICE dynamic contrast-enhanced magnetic resonance imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2011-11 |
| Est. Completion | 2022-10-26 |
| Phase | NA |
Why NCT01931709 stopped before completion
NCT01931709 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT01931709 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01931709 about?
NCT01931709 is a clinical study titled "FDG PET and DCE-MRI in Predicting Response to Treatment in Patients With Breast Cancer". This clinical trial studies fludeoxyglucose F 18 (FDG) positron emission tomography (PET) and dynamic contrast-enhanced (DCE)-magnetic resonance imaging (MRI) in predicting response to treatment in patients with breast cancer. Comparing results of diagnostic procedures done before, during, and after...
What is the current status of trial NCT01931709?
This trial is currently terminated. It is a NA study. The enrollment target is 35 participants. The study started on 2011-11. Estimated completion is 2022-10-26.
What interventions are being tested in trial NCT01931709?
The interventions under investigation include: laboratory biomarker analysis (OTHER), fludeoxyglucose F 18 (RADIATION), positron emission tomography (DEVICE), dynamic contrast-enhanced magnetic resonance imaging (DEVICE).
Who is sponsoring clinical trial NCT01931709?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01931709's enrollment target sits among peer trials
35 1564th of 2000 higher than 431 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia